Investor Information

Partnering Activity

Partnering Activity (1.5MB)


Partnering Activity (2010~)

As of October 25, 2019

Date Product name
or
Code number
(Generic name)
Indication Phase
(JP)
Phase
(Overseas)
Partner
(Agreements)
Sep
2010
KYPROLIS
(Carfilzomib)
Multiple Myeloma L L Amgen, USA
(in-license/JPN)
Sep
2011
CORALAN
(Ivabradine)
Chronic Heart Failure Approved L Servier, France
(in-license/JPN)
PARSABIV
(Etelcalcetide)
Secondary Hyperparathyroidism L L Amgen, USA
(in-license/JPN)
OPDIVO
(Nivolumab)
Melanoma
NSCLC
RCC
Hodgkin's Lymphoma
H&N Cancer
Gastric Cancer, etc.
L L BMS, USA
(out-license/except JPN, KOR & TWN)
ORENCIA
(Abatacept)
Rheumatoid Arthritis
Juvenile Idiopathic Arthritis
IV: L
SC: L
IV: L
SC: L
BMS, USA
(in-license/JPN)
Apr
2013
ONO-2370
(Opicapone)
Symptom Reemergence
in Parkinson's Disease
Filed L Bial, Portugal
(in-license/JPN)
Oct
2013
DEMSER
(Metyrosine)
Status of Catecholamine Excess Secretion in Pheochromocytoma L L Bausch Health, USA
(in-license/JPN)
Dec
2013
FORXIGA
(Dapagliflozin)
Type 2 Diabetes
Type 1 Diabetes
L L AstraZeneca, UK
(in-license/JPN)
Jul
2014
OPDIVO (Nivolumab) Melanoma
NSCLC
RCC
Hodgkin's Lymphoma
H&N Cancer
Gastric Cancer, etc.
L L BMS, USA
(out-license/JPN, KOR & TWN)
ONO-4578 Solid Tumors I I/II
YERVOY
(Ipilimumab)
Melanoma
RCC
L L BMS, USA
(in-license/JPN, KOR & TWN)
ONO-4483
(Lirilumab)
Solid Tumors I I/II
ONO-4482
(Relatlimab)
Melanoma I/II II/III
ONO-4686
BMS-986207
Solid Tumors I/II I/II
ONO-4687
(Cabiralizumab)
Pancreatic Cancer II II
ONO-7701
(Linrodostat)
Bladder Cancer III III
ONO-7807
BMS-986258
Solid Tumors I/II I/II
ONO-7911
(Bempegaldesleukin)
Solid Tumors I III
OPALMON
(Limaprost ƒ¿-CD)
Lumber Spinal Canal Stenosis L L Meiji Seika Pharma, JPN
(out-license/THA)
Dec
2014
ONO-4059
(Tirabrutinib)
Central Nervous System Lymphoma
(Btk inhibitor)
Filed | Gilead Sciences, USA
(out-license/except JPN, KOR, TWN, CHN & ASEAN)
B Cell Lymphoma, Pemphigus Sjögren Syndrome Primary Macroglobulinemia, etc.
(Btk inhibitor)
II II
Mar
2016
ONO-9054
(Sepetaprost)
Glaucoma
Ocular Hypertension
II II Santen Pharmaceutical, JPN
(out-license/Global scale)
May
2017
MEKTOVI
(Binimetinib)
BRAFTOVI
(Encorafenib)
Combination Therapy
BRAF-mutant Melanoma L L Pfizer, USA
(in-license/JPN & KOR)
BRAF-mutant Colorectal Cancer III III
Aug
2017
ONO-5704
SI-613
Osteoarthritis III | Seikagaku, JPN
(in-license/JPN)
Enthesopathy II |
Oct
2017
ONO-7705
(Selinexor)
Multiple Myeloma
Non-Hodgkin's Lymphoma
I L Karyopharm, USA
(in-license/JPN, KOR, TWN, HKG & ASEAN)
ONO-7706
(Eltanexor)
Hematological Malignancies
Solid Tumors
| I
Dec
2017
ONO-4578 Solid Tumors I I/II BMS, USA
(out-license/except JPN, KOR, TWN, CHN & ASEAN)
Jun
2019
CPI-613
(Devimistat)
Pancreatic Cancer
Acute Myeloid Leukemia
| III Rafael Pharmaceuticals, USA
(in-license/JPN, KOR, TWN & ASEAN)
Jul
2019
5F9
(Magrolimab)
Non-Hodgkin's Lymphoma
Acute Myeloid Leukemia
Myelodysplastic syndromes
Ovarian Cancer
Colorectal Cancer
| II Forty Seven, USA
(in-license/JPN, KOR, TWN & ASEAN)